A study has revealed that for patients who have had kidney transplants, treatment of focal segmental glomerulosclerosis (FSGS) with adrenocorticotropic hormone gel may be a good option. Researchers found that patients using adrenocorticotropic hormone gel went into partial or complete
Focal segmental glomerulosclerosis (FSGS) is a disease which occurs when scar tissue develops on the parts of the kidneys that filter waste from the blood (glomeruli). FSGS can be caused by a variety of conditions. Untreated, it often leads to kidney failure.
Unfortunately, even after transplantation, the risk of developing FSGS on your new kidneys persists. This led researchers to study what can be done to minimize the risk factors and ensure that post-transplant kidney health remains strong.
Adrenocorticotropic gel is usually used in cases of multiple sclerosis. Its primary function is to stimulate the release of adrenocorticotropic hormone or (ACTH), which is naturally produced by the pituitary gland and which secretes aldosterone, cortisol and corticosterone, hormones which help to regulate stress, energy and immune reactions.
Luckily, this research has observed another of ACTH gel’s positive attributes, promoting normal kidney function and in some cases staving off the kidney failure so typically seen in cases of FSGS. For more of the latest information about kidney studies and new treatments, be sure to check us out on Twitter to be the very first in the know.